Method for antagonizing vascular adhesion protein-1 (VAP-1)-mediated binding of endothelial cells to lymphocytes
US6066321A · kind A · utility
3Cited by
0References
10Claims
0Family size
Inventors
Key dates
| Filing date | May 23, 1995 |
| Grant date | May 23, 2000 |
| Priority date | — |
| Expiry date | May 23, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel endothelial cell molecule, VAP-1, is described that mediates lymphocyte binding in man. Further described are anti-VAP-1 monoclonal antibodies and methods for the diagnosis and treatment of inflammatory and autoimmune diseases by the administration of VAP-1 binding compounds, such as anti-VAP-1 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.